Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy

Sung Chul Jung, Eun Sook Park, Eun Nam Choi, Chi Hwa Kim, Su Jin Kim, Dong Kyu Jin

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is an X-linked inherited disorder caused by a deficiency of the enzyme iduronate-2-sulfatase (IDS), which results in the lysosomal accumulation of glycosaminoglycans (GAG) such as dermatan and heparan sulfate. Here, we report the generation of IDS knockout mice, a model of human MPS II, and an analysis of the resulting phenotype. We also evaluated the effect of gene therapy with a pseudotyped, recombinant adeno-associated virus 2/8 vector encoding the human IDS gene (rAAV-hIDS) in IDS-deficient mice. IDS activity and GAG levels were measured in serum and tissues after therapy. Gene therapy completely restored IDS activity in plasma and tissue of the knockout mice. The rescued enzymatic activity completely cleared the accumulated GAGs in all the tissues analyzed. This model can be used to explore the therapeutic potential of IDS replacement and other strategies for the treatment of MPS II. Additionally, AAV2/8 vectors have promising future clinical applications for the treatment of patients with MPS II.

Original languageEnglish
Pages (from-to)13-18
Number of pages6
JournalMolecules and Cells
Volume30
Issue number1
DOIs
StatePublished - Jul 2010

Keywords

  • adeno-associated virus
  • gene therapy
  • hunter syndrome
  • iduronate-2-sulfatase
  • MPS II mouse model

Fingerprint

Dive into the research topics of 'Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy'. Together they form a unique fingerprint.

Cite this